• 1. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745
• 2. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 3. Exchangeability of amino acid residues with similar physicochemical properties in coiled-coil interactions?
  Guiying Zhang,Maosheng Cheng,Yanni Li,Keliang Liu,Lifeng Cai Chem. Commun., 2013,49, 11086-11088
• 4. Excited state dynamics of symmetric and asymmetric Cr3(dpa)4Cl2 measured using femtosecond transient absorption spectroscopy?
  Chao-Han Cheng,Wen-Zhen Wang,Shie-Ming Peng,I-Chia Chen Phys. Chem. Chem. Phys., 2017,19, 25471-25477
• 5. Excitonic channels from bio-inspired templated supramolecular assembly of J-aggregate nanowires?
  Daniel Messmer,Stefan Salentinig,Jakob Heier Nanoscale, 2019,11, 6929-6938

Research Brief on Methyl (1-methyl-piperidin-4-ylmethyl)amine (CAS: 405928-19-0): Recent Advances and Applications

Methyl (1-methyl-piperidin-4-ylmethyl)amine (CAS: 405928-19-0) is a piperidine derivative that has garnered significant attention in recent chemical biology and pharmaceutical research. This compound serves as a key intermediate in the synthesis of various bioactive molecules, particularly in the development of central nervous system (CNS) targeting drugs. Recent studies have highlighted its potential as a structural motif in the design of novel receptor modulators, owing to its favorable physicochemical properties and ability to cross the blood-brain barrier.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the compound's utility in developing sigma-1 receptor ligands. Researchers utilized Methyl (1-methyl-piperidin-4-ylmethyl)amine as a core scaffold, modifying its structure to create derivatives with enhanced binding affinity (IC50 values ranging from 12-85 nM). The study revealed that the methyl group at the piperidine nitrogen and the amine functionality at the 4-position were critical for maintaining receptor interaction while allowing for structural diversification at other positions.

In neuropharmacology applications, a recent Nature Communications paper (2024) reported the use of 405928-19-0 derivatives as potential therapeutics for neurodegenerative diseases. The research team developed a series of compounds showing dual activity as acetylcholinesterase inhibitors (AChEI) and N-methyl-D-aspartate (NMDA) receptor modulators. These bifunctional agents demonstrated promising results in in vivo models of Alzheimer's disease, with one lead compound showing 40% improvement in cognitive function compared to controls.

The synthetic accessibility of Methyl (1-methyl-piperidin-4-ylmethyl)amine has been improved through recent methodological advances. A 2023 Organic Process Research & Development publication described a novel continuous flow synthesis approach that increased yield to 92% while reducing reaction time from 18 hours to just 45 minutes. This technological advancement has significant implications for scaling up production of this important pharmaceutical intermediate.

Emerging research in cancer therapeutics has also explored applications of 405928-19-0 derivatives. A 2024 study in the Journal of Biological Chemistry identified several analogs with potent histone deacetylase (HDAC) inhibitory activity. These compounds showed selective cytotoxicity against various cancer cell lines while demonstrating minimal effects on normal cells, suggesting potential for development as targeted anticancer agents.

From a drug metabolism perspective, recent pharmacokinetic studies have provided valuable insights into the compound's ADME (absorption, distribution, metabolism, and excretion) properties. Research published in Drug Metabolism and Disposition (2023) characterized the major metabolic pathways, identifying cytochrome P450 2D6 as the primary enzyme responsible for its biotransformation. This information is crucial for designing derivatives with optimized metabolic stability.

The versatility of Methyl (1-methyl-piperidin-4-ylmethyl)amine continues to be demonstrated through its incorporation into diverse therapeutic candidates. Current research directions include exploration of its use in: (1) developing novel antidepressants targeting the serotonin transporter, (2) creating next-generation antipsychotics with reduced side effect profiles, and (3) designing radiopharmaceuticals for neurological imaging. The compound's structural flexibility and proven biological activity make it a valuable building block in modern medicinal chemistry.

• 7149-42-0((1-methylpiperidin-4-yl)methanamine)
• 280-77-3(1-Azabicyclo[3.3.1]nonane)
• 65017-57-4(4-(Aminomethyl)-1-(n-butyl)piperidine)
• 14446-76-5(Piperidine,1,3,5-trimethyl-, (3R,5S)-rel-)
• 32470-52-3(4-[(piperidin-1-yl)methyl]piperidine)
• 2162-86-9(1-Ethyl-3-methylpiperidine)
• 116905-90-9(4-Piperidinemethanamine,N,N-diethyl-)
• 16544-52-8(Piperidine,1,3,5-trimethyl-, (3R,5R)-rel-)
• 27644-32-2(Piperidine,1,3,5-trimethyl-)
• 62171-81-7(Piperidine, 1,3,4-trimethyl-)